联系方式

电子邮箱:lijiali5@mail.sysu.edu.cn

 

简单介绍

李嘉丽,副教授,硕士生导师,2010年获中山大学药理学博士学位并留校任教,目前担任广东省药理学会临床治疗药物监测研究专业委员会委员。研究方向为遗传药理学与药物基因组学、临床药理学。已主持国家自然科学基金、中国博士后科学基金、广东省自然科学基金及广东省医学科研基金共4项,作为项目骨干参与国家重点研发项目、“重大新药创制”科技重大专项、国家自然科学基金重大国际合作研究项目/重点项目/面上及青年项目、省市级科研基金等多个项目。2012 年入选广东省高等学校“千百十工程”第七批校级培养对象,2017年获中国药理学会青年药理学家奖。已在国内外期刊发表论文近70篇(其中SCI收录38篇,第一作者及通讯作者15篇),其中作为第一作者已在Pharmacogenomics J、Pharmacogenomics、Drug Metab Dispos三本药物基因组学与药物代谢领域的权威杂志发表文章4篇。参编教材2部,并参编高新技术科普丛书《量体裁药不是梦-从基因到个体化用药》。担任Eur J Pharm Sci 、Pharmacogenomics等国内外学术期刊审稿人。

 

研究方向

1. 遗传药理学
2. 药物基因组学
3. 临床药理学

 

教育经历

1.2000.09~2004.06:中山大学药学院,药学专业,获学士学位
2.2004.09~2010.06:中山大学药学院,药理学专业,获博士学位

 

工作经历

2010.07~2018.03,中山大学,药学院,讲师
2018.04至今,中山大学,药学院,副教授

 

科研项目

1. 基于遗传因素及病理生理状态的肾移植术后早期他克莫司个体化用药研究(项目编号:81102515),国家自然科学基金,2012.01~2014.12 主持
2. 基于基因多态性及DNA甲基化影响下的他克莫司个体化用药研究(项目编号:2016A030313219),广东省自然科学基金项目, 2016.06~2019.06 主持
3. 基于遗传因素及病理生理状态的肾移植术后早期他克莫司个体化用药研究(项目编号:20110490973),中国博士后科学基金,2011.04~2012.12 主持
4. 相关基因多态性及microRNA表达水平对他克莫司浓度影响的研究(项目编号:B2011067),广东省医学科研基金, 2011.01~2012.12 主持
5. 基于药物基因组学和定量药理学的甲氨蝶呤治疗幼年特发性关节炎儿童的个体化用药研究(项目编号:81603203),国家自然科学基金,2017.01-2019.12 合作单位负责人
6. 基于TGF-βl和NOX的五酯片抵抗他克莫司慢性肾毒性的作用及新机制研究 (项目编号:81703609),国家自然科学基金,2018.01-2020.12 合作单位负责人

 

论著专利

1. Zheng Z, Zhang S, Ma W, Zhang L, Huang L, Huang W, Huang M, Wang Z*, Li Jiali*.Determination of dexmedetomidine by UHPLC-MS/MS and its application to evaluate the effect of dexmedetomidine concentration on the target-controlled infusion concentration of propofol.J Pharm Biomed Anal. 2018 May 30;154:438-443.
2.Li Jiali,Chen SY, Qin XL,Fu Qian,Bi HC, Zhang Y, Wang XD, Liu LS, Wang CX*, Huang Min*. Wuzhi Tablet (Schisandra sphenanthera Extract) is a Promising Tacrolimus-Sparing Agent for Renal Transplant Recipients Who are CYP3A5 Expressers: a Two-Phase Prospective Study. Drug Metab Dispos, 2017, 45(11):1114-1119.
3. Peng LL#, Zhao YQ#, Zhou ZY, Jin J, Zhao M, Chen XM, Chen LY, Cai YF*, Li Jiali*, Huang M*. Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin. 2016;37(11):1442-1448. 
4. Liu S, Chen RX, Li J, Zhang Y, Wang XD, Fu Q, Chen LY, Liu XM, Huang HB, Huang M, Wang CX*, Li Jiali*. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients. Acta Pharmacol Sin. 2016;37(9):1251-1258. 
5. Li Jiali, Liu S, Fu Q, Zhang Y, Wang XD, Liu XM, Liu LS, Wang CX*, Huang M*. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015;16(12):1355-1365.
6. Xie XC#, Li J#, Wang HY, Li HL, Liu J, Fu Q, Huang JW, Zhu C, Zhong GP, Wang XD, Huang M, Wang CX*, Li Jiali*. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients. Acta Pharmacol Sin. 2015;36(5):644-650. 
7. Liu XM#, Li Jiali#, Fu Q, Liu S, Zhang Y, Wang XD, Wang HY, Li J, Zhu C, Wang CX*, Huang M*. Associations of HSD11B1 Polymorphisms with Tacrolimus Concentrations in Chinese Renal Transplant Recipients with Prednisone Combined Therapy. Drug Metab Dispos. 2015;43(4):455-458. 
8. Wang YX#, Li Jiali#, Wang XD, Zhang Y, Wang CX*, Huang M*. Diltiazem augments the influence of MDR1 genotype status on cyclosporine concentration in Chinese patients with renal transplantation. Acta Pharmacol Sin. 2015;36(7):855-862.
9. Zhang Y#, Li Jiali#, Fu Q, Wang XD, Liu LS, Wang CX*, Xie W, Chen ZJ, Shu WY, Huang M*. Associations of ABCB1, NFKB1, CYP3A and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. Acta Pharmacol Sin. 2013;34(4):555-560. 
10. Chen SY#, Li Jiali#, Meng FH, Wang XD, Liu T, Li J, Liu LS, Fu Q, Huang M*, Wang CX*. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism - a prospective, randomized, controlled study. Clin Transplant. Clin Transplant. 2013;27(3):E272-281. 
11. Deng XY, Wang CX, Wang XD, Bi HC, Chen X, Li Jiali*, Huang M*. Genetic polymorphisms of UGT1A8, UGT1A9, UGT2B7 and ABCC2 in Chinese renal transplant recipients and a comparison with other ethnic populations. Pharmazie.2013;68(4):240-244.
12. Lai Y, Huang M, Li H, Wang XD, Li Jiali*. Distinct genotype distribution and haplotype profiles in MDR1 gene among Chinese Han, Bai, Wa and Tibetan ethnic groups. Pharmazie. 2012;67(11):938-941. 
13. Li Jiali#, Wang XD#, Chen SY, Liu LS, Fu Q, Chen X, Teng LC, Wang CX*, Huang M*. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective. Pharmacogenomics J. 2011;11(4):300-306.
14. Li Jiali, Wang XD, Wang CX, Fu Q, Liu LS, Huang M*, Zhou SF*. Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: application to a clinical drug-drug interaction study. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;867(1):111-118. 
15. Wang XD#, Li Jiali#, Su QB, Deng XY, Lu Y, Chen J, Zhang JX, Zhao LZ, Zuo Z, Chan E, Chen X, Chowbay B, Xue CC, Huang M*, Zhou SF*. A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab. 2007;8(8):778-786.

 

获奖情况

2017年荣获“中国药理学会青年药理学家奖”